drugset / Trial / NCT03620526

Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction

NCT03620526

Phase 4 Unknown 34 enrolled National Taiwan University Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

BACKGROUND There is no effective medical treatment for heart failure with preserved ejection fraction (HFpEF). Increases in pulmonary capillary wedge pressure (PCWP) develop in patients with HFpEF. Prostacyclin analogo can possible reduced PA pressure along with PWCP pressure, as with exercise. OBJECTIVES This study try to determine whether inhlalation of iloprost improves exercise hemodynamics and cardiac reserve in HFpEF. METHODS In a double-blind, randomized, placebo-controlled, parallel-group trial, subjects with HFpEF underwent invasive cardiac catheterization with simultaneous expired gas analysis at rest and during exercise, before and 15 min after treatment with either inhaled iloprost or matching placebo.

Timeline

Start
2017-11-29
Primary completion
2020-01-01
Completion
2020-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloprost Other / unclassified 10 ug/ml Inhaled
Subject Iloprost Other / unclassified 50 mg/kg Inhaled